Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Summary

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

Yes

Interventions

• Other
  Statement communicating uncertainty with a single arm trial

  Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.

• Other
  Statement communicating uncertainty with limited study duration

  Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.

• Other
  Statement communicating uncertainty with a limited study population

  Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.

• Other
  Statement communicating uncertainty with an unvalidated surrogate endpoint

  Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.

• Other
  Statement communicating uncertainty with treatment effect size

Location